FDA decision: Atacicept by Vera Therapeutics (in July 2026)

FDA decision: Atacicept by Vera Therapeutics (in July 2026)

$13 vol

Order book

Market Rules

Resolves Yes if the FDA's decision on Atacicept by Vera Therapeutics in July 2026 is a full approval or an accelerated approval.Outcome verified from AppliedXL.

This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.

Atacicept is an investigational biological medicine developed by Vera Therapeutics that acts as a "double interceptor," blocking two proteins — called BAFF and APRIL — that instruct the immune system's B cells to overproduce a defective form of the antibody IgA. Think of BAFF and APRIL as two fuel lines feeding an immune fire in the kidney; atacicept is designed to shut off both simultaneously, dampening the abnormal immune response that drives kidney damage in IgA nephropathy (IgAN).

Note: this event is mutually exclusive.

Timeline and payout

Market openJun 17, 2026 · 5:00pm EDT

Market closesAfter the outcome occurs

Projected payout30 minutes after closing

This market will close early if the FDA issues a decision on Atacicept before Aug 1, 2026 Otherwise, it closes by Jul 31, 2026 at 11:59pm EDT.

SeriesKXATACICEPT

EventKXATACICEPT-26

MarketKXATACICEPT-26-Y

Insider trading is prohibited

The following are prohibited from trading this contract:

Persons who are employed by any of the Source Agencies are not permitted to trade on the Contract.
Persons who hold any material, non-public information on the Underlying are not permitted to trade on the Contract.